Acute Dosage With Dexrazoxane, but not Doxorubicin, Is Associated With Increased Rates of Hepatic Protein Synthesis in vivo

Toxicologic Pathology

Volumn 29, Issue 6, 2001, Pages 591-599

  Zima, Tomas ^a   Tesar, Vladimir ^a   Sherwood, Roy ^b   Sood, Alka ^b   au, Lai Chong ^b   Richardson, Peter J ^b   Preedy, Victor R ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c NONE

Author keywords

cytotoxicity; dexrazoxane; doxorubicin; fl ooding dose; Liver; liver function; protein synthesis; rat

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; DOXORUBICIN; LIVER PROTEIN; PHENYLALANINE; RAZOXANE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; LIVER FUNCTION; LIVER METABOLISM; LIVER TOXICITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; RAT; RNA ANALYSIS;

ALKALINE PHOSPHATASE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ASPARTATE AMINOTRANSFERASES; DOXORUBICIN; DRUG SYNERGISM; INJECTIONS, INTRAPERITONEAL; LIVER; MALE; PROTEIN BIOSYNTHESIS; RATS; RATS, WISTAR; RAZOXANE; SERUM ALBUMIN;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0035677759     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/019262301753385915     Document Type: Article

References (59)

1. Anderson H., Roberge M. (1996). Topoisomerase II inhibitors affect entry into mitosis and chromosome condensatio n in BHK cells. Cell Growth Differ 7: 83-90.
2. Bagchi D., Bagchi M., Hassoun EA, Kelly J., Stohs SJ (1995). Adriamycin-induced hepatic and myocardial lipid peroxidation and DNA damage, and enhanced excretion of urinary lipid metabolites in rats. Toxicology 95: 1-9.
3. Davis TA, Fiorotto ML, Nguyen HV, Burrin DG (1999). Amino-tRNA and tissue free amino acid pools are equilibriated after a fl ooding dose of phenylalanine. Am J Physiol 277: E103-E109.
4. Della Torre P., Mazue G., Podesta A., Moneta D., Sammartini U., Imondi AR (1999). Protection against doxorubicin-induce d cardiotoxicity in weanling rats by dexrazoxane. Cancer Chemother Pharmacol 43: 151-156.
5. El Hage AN, Herman EH, Ferrans VJ (1983). Examination of the protective effect of ICRF-187 and dimethyl sulfoxide against acetaminophen-induce d hepatotoxicity in Syrian golden hamsters. Toxicology 28: 295-303.
6. Fardel O., Lecureur V., Daval S., Corlu A., Guillouzo A. (1997). Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Eur J Biochem 246: 186-192.
7. Fattman CL, Allan WP, Hasinoff BB, Yalowich JC (1996). Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells. Biochem Pharmacol 52: 635-642.
8. Ferrans VJ, Clark JR, Zhang J., Yu ZX, Herman EH (1997). Pathogenesis and prevention of doxorubicin cardiomyopathy. Tsitologiia 39: 928-937.
9. Garlick PJ, McNurlan MA, Preedy VR (1980). A rapid and convenient technique for measuring the rate of protein synthesis in tissues by injection of [3H]phenylalanine. Biochem J 192: 719-723.
10. Gornall HG, Bardawill CJ, David MM (1949). Determination of serum proteins by means of the Biuret reaction. J Biol Chem 177: 751-766.
11. Hasinoff BB (1989). The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin. Agents Actions 26: 378-385.
12. Hasinoff BB (1998). Chemistry of dexrazoxane and analogues. Semin Oncol 25: 3-9.
13. Hasinoff BB, Abram ME, Chee GL, Huebner E., Byard EH, Barnabe N., Ferrans VJ, Yu ZX, Yalowich JC (2000). The catalytic DNA topoisomeras e II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells. J Pharmacol Exp Ther 295: 474-483.
14. Hasinoff BB, Aoyama RG (1999). Stereoselective metabolism of dexrazoxane (ICRF-187) and levrazoxane (ICRF-186). Chirality 11: 286-290.
15. Hasinoff BB, Kuschak TI, Yalowich JC, Creighton AM (1995). A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol 50: 953-958.
16. Hasinoff BB, Reinders FX, Clark V. (1991). The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5dioxopiperazinyl-1-yl)propane. Drug Metab Dispos 19: 74-80.
17. Hasinoff BB, Yalowich JC, Ling Y., Buss JL (1996). The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediate dgrowth inhibition of Chinese hamster ovary cells. Anticancer Drugs 7: 558-567.
18. Herman EH, Zhang J., Chadwick DP, Ferrans VJ (2000). Comparison of the protective effects of amifostine and dexrazoxan e against the toxicity of doxorubicin in spontaneously hypertensive rats. Cancer Chemother Pharmacol 45: 329-334.
19. Herman EH, Zhang J., Ferrans VJ (1994). Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats. Cancer Chemother Pharmacol 35: 93-100.
20. Holm B., Jensen PB, Sehested M. (1996). ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomeras e II poisons to CNS tumors. Cancer Chemother Pharmacol 38: 203-209.
21. Imondi AR (1998). Preclinical model s of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects. Semin Oncol 25: 22-30.
22. Imondi AR, Della Torre P., Mazue G., Sullivan TM, Robbins TL, Hagerman LM, Podesta A., Pinciroli G. (1996). Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs. Cancer Res 56: 4200-4204.
23. Khelifa T., Beck WT (1999). Induction of apoptosis by dexrazoxane (ICRF-187) through caspases in the absence of c-jun expression and c-Jun NH2-terminal kinase 1 (JNK1) activation in VM-26-resistantCEM cells. Biochem Pharmacol 58: 1247-1257.
24. Kirby GM, Bach PH (1995). Enhanced hexachloro-1:3-butadien e nephrotoxicity in rats with a preexisting adriamycin-induced nephrotic syndrome. Toxicologic Pathology 23: 303-312.
25. Koyama I., Arai K., Sakagishi Y., Ikezawa H., Komoda T. (1987). Blood appearance of rat alkaline phosphatas e originating from the duodenu m in vitro. J Chromatogr 420: 275-286.
26. Kvetina J., Grossmann V., Svoboda Z., Safarova M. (1997). Preclinical comparison of bis-diketopiperazine-propan e (dexrazoxane) and bis-diketopiperazine-ethane (antimet) on the adriamycin-cardiotoxi c effect. Neoplasma 44: 97-99.
27. Lear L., Nation RL, Stupans I. (1992). Effects of cyclophosphamid e and adriamycin on rat hepatic microsomal glucuronidation and lipid peroxidation. Biochem Pharmacol 44: 747-753.
28. Leo E., Arletti R., Forni F., Cameroni R. (1997). General and cardiac toxicity of doxorubicin-loade d gelatin nanoparticles. Farmaco 52: 385-388.
29. Merski JA, Daskal I., Busch H. (1976). Effects of adriamycin on ultrastructure of nucleoli in the heart and liver cells of the rat. Cancer Res 36: 1580-1584.
30. Monti E., Sinha BK (1990). Potentiation of doxorubicin cytotoxicity by (+)-1,2-bis-(3,5-dioxopiperazinyl-1-yl) propane (ICRF-187) in human leukemic HL-60 cells. Cancer Commun 2: 145-149.
31. Morgan SE, Beck WT (2001). Role of an inverted CCAAT element inhuman topoisomeras e II alpha gene expression in ICRF-187-sensitive and -resistant CEM leukemic cells. Mol Pharmacol 59: 203-211.
32. Mungikar AM, Gothoskar BP (1985). Depression of mouse liver microsomal mixed function oxidase enzymes by adriamycin. Toxicol Lett 29: 17-23.
33. Munro HN, Fleck A. (1969). Analysis of tissues and body fl uids for nitrogenous constituents. In: Mammalian Protein Metabolism, Anonymous Academic Press, New York, pp 423-586.
34. O'Leary M., Ferguson J., Hinds C., Coakley J., Preedy VR (1998). Fractional rates of liver protein synthesis (PS) in sepsis in the rat: relation to glutamine (Gln) levels. Intensive Care Med 24 (Supplement 1): S74.
35. Ogura R., Sugiyama M., Haramaki N., Hidaka T. (1991). Electron spin resonance studies on the mechanism of Adriamycin-induced heart mitochondria l damages. Cancer Res 51: 3555-3558.
36. Pierscinski G., Drzewoski J., Nowak D. (1994). The infl uence of doxorubicin and 4’-epi-doxorubicin on lipid peroxidation in mouse heart, lungs and liver. Part II. Pol J Pharmacol 46: 55-59.
37. Preedy VR, Marway JS, Baldwin D., Paice AG, Jones J., Wassif WS, Scott D. (1996). Experimental D-penicillamine-induced myopathy. Biochem Soc Trans 24: 266S.
38. Preedy VR, McIntosh A., Bonner AB, Peters TJ (1996). Ethanol dosage regimens in studies of ethanol toxicity: infl uence of nutrition and surgical interventions. Addict Biol 1: 255-262.
39. Preedy VR, Why H., Paice AG, Reilly ME, Ansell H., Patel VB, Richardson PJ (1995). Protein synthesi s in the heart in vivo, its measurement and pathophysiologica l alterations. Int J Cardiol 50: 95-106.
40. Rajagopalan S., Politi PM, Sinha BK, Myers CE (1988). Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res 48: 4766-4769.
41. Rapozzi V., Comelli M., Mavelli I., Sentjurc M., Schara M., Perissin L., Giraldi T. (1999). Melatonin and oxidative damage in mice liver induced by the prooxidant antitumor drug, adriamycin. In Vivo 13: 45-50.
42. Samelis GF, Stathopoulos GP, Kotsarelis D., Dontas I., Frangia C., Karayannacos PE (1998). Doxorubicin cardiotoxicity and serum lipid increase is prevented by dextrazoxane (ICRF-187). Anticancer Res 18: 3305-3309.
43. Sehested M., Jensen PB (1996). Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol 51: 879-886.
44. Seymour L., Bramwell V., Moran LA (1999). Use of dexrazoxane as a cardioprotectant in patients receiving doxorubici n or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 3: 145-159.
45. Shinozawa S., Gomita Y., Araki Y. (1991). Effect of aclarubicin and doxorubicin on rat liver mitochondrial oxidative phosphorylation. Physiol Chem Phys Med NMR 23: 101-106.
46. Siddiq T., Richardson PJ, Hashim IA, Preedy VR (1991). Effect of acute anaesthesi a on synthesis of contractile and non-contractile proteins of heart muscle and mixed proteins of types I and II fi bre rich skeletal muscles of rat. Cardiovasc Res 25: 314-318.
47. Siddiq T., Richardson PJ, Sherwood RA, Preedy VR (1992). Protein synthesis in pulmonary, cardiac, and skeletal muscle in acute hypertension induced by aortic constriction in the rat. Cardiovasc Res 26: 72-81.
48. Sparano JA (1998). Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations. Semin Oncol 25: 66-71.
49. Swain SM (1998). Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. Semin Oncol 25: 43-47.
50. Vats T., Kamen B., Krischer JP (1991). Phase II trial of ICRF-187 in children with solid tumors and acute leukemia. Invest New Drugs 9: 333-337.
51. Villani F., Galimberti M., Monti E., Cova D., Lanza E., Rozza-Dionigi A., Favalli L., Poggi P. (1990). Effect of ICRF-187 pretreatment against doxorubicin-induce d delayed cardiotoxicity in the rat. Toxicol and Appl Pharmacol 102: 292-299.
52. Weiss G., Kastner S., Brock J., Thaler J., Grunewald K. (1997). Modulation of transferrin receptor expression by dexrazoxane (ICRF-187) via activation of iron regulatory protein. Biochem Pharmacol 53: 1419-1424.
53. Wexler LH, Andrich MP, Venzon D., Berg SL, Weaver-McClure L., Chen CC, Dilsizian V., Avila N., Jarosinski P., Balis FM, Poplack DG, Horowitz ME (1996). Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 14: 362-372.
54. Yeung TK, Jaenke RS, Wilding D., Creighton AM, Hopewell JW (1992). The protective activity of ICRF-187 against doxorubicin-induce d cardiotoxicity in the rat. Cancer Chemother Pharmacol 30: 58-64.
55. Zhang J., Clark JR, Jr, Herman EH, Ferrans VJ (1996). Doxorubicin-induce d apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187. J Mol Cell Cardiol 28: 1931-1943.
56. Zhang J., Herman EH, Ferrans VJ (1994). Effects of ICRF-186 [(L)1,2bis(3,5-dioxopiperazinyl-1-yl)propane] on the toxicity of doxorubicin in spontaneously hypertensive rats. Toxicology 92: 179-192.
57. Zhang Y., Hua HY, Zhang TM (1993). Inhibitory effect of dioxopiperazine compounds on malondialdehyde formation induced by doxorubicin in rat liver mitochondria in vitro. Chung Kuo Yao Li Hsueh Pao 14: 340-343.
58. Zima T., Tesar V., Crkovska J., Stejskalova A., Platenik J., Teminova J., Nemecek K., Janebova M., Stipek S. (1998). ICRF-187 (dexrazoxan) protects from adriamycin-induce d nephrotic syndrome in rats. Nephrol Dial Transplant 13: 1975-1979.
59. Zima T., Tesar V., Richardson PJ, Mantle D., Preedy VR (2001). Effects of doxorubicin (adriamycin) and [(+)-1,2-bis(3,5-dioxopiperazinyl1-yl)]propane (ICRF-187) on skeletal muscle protease activities. Toxicol Appl Pharmacol. In press.